Acta Med. 2003, 46: 195-199

https://doi.org/10.14712/18059694.2019.33

Clinical Assessment of 324 Breast Cancer Cases in Two Centers Between the Years of 1992 and 2002

Ali Borazana, Hasan Üstünb, Faruk Aksoyc, Celalettin Vatansevc, Zafer Cantürkd, Muharrem Akkaşa, Şamil Ecirlie, Ahmet Yılmaza

aKocaeli University, Faculty of Medicine, Department of Internal Medicine, Turkey
bKocaeli University, Faculty of Medicine, Department of Medical Oncology, Turkey
cSelcuk University, Faculty of Medicine, Department of General Surgery, Turkey
dKocaeli University, Faculty of Medicine, Department of General Surgery, Turkey
eSelcuk University, Faculty of Medicine, Department of Internal Medicine, Turkey

Received May 1, 2003
Accepted July 1, 2003

References

1. Aapro MS. Adjuvant therapy of primary breast cancer: A review of key findings from the 7th international conference, St. Gallen, February 2001. The Oncologist 2001; 6:376–85. <https://doi.org/10.1634/theoncologist.6-4-376>
2. Aebi S, Gelber S, Castiglione-Gertsch M et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000; 355:1869–74. <https://doi.org/10.1016/S0140-6736(00)02292-3>
3. Anderson DE. Breast: Genetic study of breast cancer: Identification of a high risk group. Cancer 1974; 34:1090–7. <https://doi.org/10.1002/1097-0142(197410)34:4<1090::AID-CNCR2820340419>3.0.CO;2-J>
4. Baquet CR, Commiskey P. Socioeconomic factors and breast carcinoma in multicultural woman. Cancer 2000; 88:1256–64. <https://doi.org/10.1002/(SICI)1097-0142(20000301)88:5+<1256::AID-CNCR13>3.0.CO;2-3>
5. Cardosa F, Di Leo A, Lohrisch C et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 2002; 13:197–207. <https://doi.org/10.1093/annonc/mdf101>
6. Carter C, Allen C, Henson D. Relation of tumor size, lymph node status and survival in 24.740 breast cancer cases. Cancer 1989; 63:181–7. <https://doi.org/10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H>
7. Cuzick J. A brief review of the current breast cancer prevention trials and proposals for future trials. Eur J Cancer 2000; 36:1298–302. <https://doi.org/10.1016/S0959-8049(00)00106-4>
8. Forbes JF. The control of breast cancer: the role of tamoxifen. Semin Oncol 1997; 24(1Suppl 1):S1–5–S1–19.
9. Freeman HP. Cancer in economically disadvantaged. Cancer 1989; 64(1Suppl 1): 324–34; discussion 342–345. <https://doi.org/10.1002/1097-0142(19890701)64:1+<324::AID-CNCR2820641334>3.0.CO;2-B>
10. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer-V Update 1998. J Natl Cancer Inst 1998; 90:1601–8. <https://doi.org/10.1093/jnci/90.21.1601>
11. Greenlee RT, Murray T, Bolden S et al. Cancer statistics, 2000. CA Cancer J Clin 2000; 50:7–33. <https://doi.org/10.3322/canjclin.50.1.7>
12. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339:974–84.20. <https://doi.org/10.1056/NEJM199810013391407>
13. Lacey JV Jr, Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Env Mol Mutagenesis 2002; 39:82–8. <https://doi.org/10.1002/em.10062>
14. Martin AM, Weber BL. Genetic and hormonal risk faktors in breast cancer. J Natl Cancer Inst 2000; 92:1126–35. <https://doi.org/10.1093/jnci/92.14.1126>
15. Mathieu E, Merviel P, Barranger E et al. Breast cancer and pregnancy: review of the literature. J Gynecol Obstet Biol Reprod (Paris) 2002; 31:233–42.
16. McKean-Cowdin R, Feigelson HS, Ross RK et al. Declining cancer rates in the 1990s. J Clin Oncol 2000; 18:2258–68. <https://doi.org/10.1200/JCO.2000.18.11.2258>
17. Morrison AS, Brisson J, Khalid N. Breast cancer incidence and mortality in the Breast Cancer Detection Demonstration Project. J Natl Cancer Inst 1988; 80: 1540–7. <https://doi.org/10.1093/jnci/80.19.1540>
18. National Institute of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst 2001; 93:979–89.
19. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancer in 1990. Int J Cancer 1999; 80:827–41. <https://doi.org/10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P>
20. Peto R, Boreham J, Clark M et al. UK and USA breast cancer deaths down 25 % in year 2000 at ages 20–69 years. Lancet 2000; 355:1822. <https://doi.org/10.1016/S0140-6736(00)02277-7>
21. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. [published erratum. Int J Cancer 83:18–29;1999]. Int J Cancer 1999; 83:870–3. <https://doi.org/10.1002/(SICI)1097-0215(19991210)83:6<870::AID-IJC35>3.0.CO;2-9>
22. Seidman H, Mushinski MH, Gelb SK, Silverberg E. Probabilities of eventually developing or dying of cancer. United States CA Cancer J Clin. 1985; 35: 36–56. <https://doi.org/10.3322/canjclin.35.1.36>
23. Smith J, Gamez-Araujo JJ, Gallager HS et al. Carcinoma of the breast: Analysis of total lymph node involvement versus level of metastasis. Cancer 1977; 39:527–32. <https://doi.org/10.1002/1097-0142(197702)39:2<527::AID-CNCR2820390221>3.0.CO;2-N>
24. Wingo PA, Ries LA, Rosenberg HM, et al. Cancer incidence and mortality, 1973–1995: a report card for the U.S. Cancer 1998; 82:1197–207. <https://doi.org/10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive